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This report describes the detection of Citrobacter 
koseri carrying K.  pneumoniae carbapenemase (KPC-
2) isolated in July 2011 from a Greek patient, who was 
also colonised by a Klebsiella pneumoniae strain co-
producing KPC-2 and Verona integron-encoded met-
allo-beta-lactamase (VIM)-1. 
Case description
On July 2011, a Greek male in his early 80s was admit-
ted to the University Hospital of Larissa, Greece, due to 
an acute myocardial infarction. He had chronic hyper-
tension due to diabetes and had been hospitalised in 
the same hospital two months earlier, due to suspi-
cion of tuberculosis, which was later ruled out (sputum 
and bronchoalveolar lavage cultures were negative 
for Mycobacterium tuberculosis). His respiratory tract 
symptoms soon remitted and he was discharged.
On admission for the myocardial infarction in July, he 
was given an empirical prophylactic antibiotic regi-
men of amoxicillin and clindamycin. On the fourth day 
of hospitalisation, he became febrile (40 °C) and cul-
tures taken from various samples (blood, vein cath-
eter, urine, sputum and bronchoalveolar lavage) were 
examined. Gram staining of the bronchoalveolar lavage 
showed the presence of Gram-negative rods along with 
leucocyte infiltration, indicating a respiratory tract 
infection. The presence of the Gram-negative bacte-
rium was confirmed by culture, while the rest of the 
clinical samples were negative.
Using the VITEK 2 system (bioMérieux, France), the iso-
late was found to be Citrobacter koseri with reduced 
susceptibility or resistance to beta-lactams, includ-
ing carbapenems (cefotaxime, ceftazidime, cefepime, 
aztreonam and ertapenem), but susceptible to fluoro-
quinolones (ciprofloxacin) and aminoglycosides (ami-
kacin and gentamicin) (Table). Identification of C. koseri 
was further confirmed by PCR (amplifying the 16S 
ribosomal (r) RNA) and sequencing [1]. Non-beta-lactam 
antibiotics, such as quinolones and aminoglycosides, 
were active against the isolate (Table). The antimi-
crobial chemotherapy was altered to ciprofloxacin 
and the fever abated within days. Screening of faecal 
samples for carbapenem-resistant Enterobacteriaceae 
performed with McConkey agar supplemented with 
1mg/L imipenem showed that the patient’s gastroin-
testinal tract was colonised by an imipenem-resistant 
Klebsiella pneumoniae (Table).
Ten days later and while still on treatment with cipro-
floxacin, the patient had a second febrile episode and 
imipenem-non-susceptible K.  pneumoniae isolates 
were recovered from three cultures (two from blood 
and one from a vein catheter). The antibiotic resistance 
profiles of these three isolates were similar to that 
of the K.  pneumoniae isolate from the faecal sample 
(Table). The patient was then successfully treated with 
a combination of tigecycline and gentamicin.
Background
The emergence of Enterobacteriaceae producing class 
A beta-lactamases of K.  pneumoniae carbapenemase 
(KPC) type is a major clinical and public health concern 
as these enzymes have the potential to compromise 
treatment with all beta-lactams, including carbapen-
ems. They are typically transposon-encoded determi-
nants and therefore have the ability to move between 
plasmids and across bacterial species.
C. koseri, an environmental, Gram-negative bacterium, 
is occasionally found as a coloniser of the human gas-
trointestinal tract.* Although the potential virulence of 
the species is considered low, it is sporadically impli-
cated in serious nosocomial infections [2]. Furthermore, 
C. koseri has the ability to easily incorporate antibiotic-
resistance determinants [3]. Although there are several 
reports of C.  koseri isolates bearing extended-spec-
trum beta-lactamase (ESBL) genes, the detection of 
C.  koseri isolates producing a carbapenemase is rare 
[4-6]. To our knowledge, there is only one report of a 
C.  koseri isolate producing Verona integron-encoded 
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metallo-beta-lactamase VIM-(1) [7]. Here, we present 
the first report of a C. koseri clinical isolate producing 
KPC-2.
Laboratory investigations
All five bacterial strains isolated from the patient (one 
C. koseri and four K. pneumoniae) were studied further. 
The minimum inhibitory concentration of various antio-
biotics were determined by Etest (bioMérieux, France) 
and the results were interpreted according to the cri-
teria of the European Committee on Antimicrobial 
Susceptibility Testing [8]. The modified Hodge test 
was used for phenotypic detection of carbapenemase 
production of either KPC or VIM type: all five isolates 
were positive. Meropenem-boronate and meropenem-
ethylenediaminetetraacetic acid (EDTA) combined disk 
tests, performed as described elsewhere [9], indicated 
the presence of a KPC in the C.  koseri isolate and the 
co-production of KPC and metallo-beta-lactamase 
(MBL) in the K. pneumoniae isolates.
PCR assays were used to screen all five isolates for 
bla genes encoding KPC, VIM, SHV, TEM, OXA-1, CMY 
and CTX-M [10-12]. Sequencing of the entire amplified 
genes revealed the carriage of blaTEM-1 and blaKPC-2 by 
C. koseri and blaTEM-1, blaKPC-2, and blaVIM-1 by K. pneumo-
niae. No nucleotide differences were observed in the 
blaTEM-1 and blaKPC-2 genes (which are known to be highly 
conserved) in the C. koseri and K. pneumoniae isolates.
The genetic relatedness of the K. pneumoniae isolates 
was investigated by multilocus sequence typing based 
on seven housekeeping genes (rpoB, gapA, mdh, pgi, 
phoE, infB and tonB) [13]. All four isolates were found 
to belong to ST147.
It was not possible to determine whether C.  koseri 
could be found in the patient’s gastrointestinal tract. 
Detection of C.  koseri in faecal samples relies on 
amplification of 16S rRNA by PCR; however, this would 
amplify almost all bacteria that colonise the gastroin-
testinal tract.
Control measures taken
As recommended by the Greek health authorities, 
patients are not screened for carbapenem-resistant 
bacteria on admission or during hospitalisation. Weekly 
carrier screening is performed only in wards where a 
carbapenemase-producing bacterium is isolated.
When C.  koseri was isolated from the patient, faecal 
samples were taken from the other six patients who 
were being treated in the same unit. None were found 
to be colonised by a KPC-positive Enterobacteriaceae. 
The patient was isolated in a single-bed room, under 
strict infection control measures.
Discussion
Previous studies have presented evidence for horizon-
tal dissemination of blaKPC genes among enterobacterial 
species worldwide [14-17]. However, to our knowledge, 
this is the first report of C. koseri producing KPC-2.
Enterobacteriaceae producing KPC were introduced in 
Greece in 2007 [18]. Since then, the prevalence of these 
microorganisms has risen to epidemic proportions, 
especially in teaching hospitals in the main urban 
areas [19]. This can be attributed to the overcrowded 
patient population in these hospitals, serious shortage 
of specialised personnel and consequently inadequate 
infection control. In the hospital in Larissa, where the 
prevalence of KPC-positive K.  pneumoniae is approxi-
mately 27%, similar to that in other teaching hospitals 
in Greece [20], isolates of various species, such as 
Serratia marcencens, Escherichia coli and Enterobacter 
aerogenes carrying blaKPC genes have been occasion-
ally isolated from infected or colonised patients.
Table 
Minimum inhibitory concentrations of various antimicrobial agents against isolated bacteria from a hospitalised patient, 
Greece, July 2011
Isolate (type of sample)
Etest results for the antimicrobial agents (mg/L and interpretationa)
IMP MEM ERT CTX CAZ FEP ATM COL TIG CIP GM AN
Citrobacter koseri
(bronchoalveolar lavage)
n=1
0.75
S
0.19
S
8
R
4
R
2
NS
1.5
NS
4
R
0.25
S
0.25
S
0.25
S
0.19
S
2
S
Klebsiella pneumoniae 
(blood)
n=2
32
R
16
R
32
R
64
R
256
R
32
R
64
R
16
R
0.5
S
16
R
1
S
12
NS
K. pneumoniae 
(vein catheter)
n=1
32
R
16
R
32
R
64
R
256
R
32
R
64
R
16
R
0.5
S
16
R
1
S
12
NS
K. pneumoniae 
(faecal)
n=1
32
R
16
R
32
R
64
R
256
R
32
R
64
R
16
R
0.5
S
16
R
1
S
12
NS
AN: amikacin; ATM: aztreonam; CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin; CTX: cefotaxime; ERT: ertapenem; FEP: cefepime;  
GM: gentamicin; IMP: imipenem; MEM: meropenem; TIG: tigecycline. 
a R: resistant; NS: non-susceptible; S: sensitive.
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The fact that the patient in this report was colonised 
by a KPC-positive K. pneumoniae in his gastrointestinal 
tract suggests the in vivo transfer of blaKPC-2 to C. koseri. 
Given that K. pneumoniae was not isolated from bron-
choalveolar lavage cultures, it is most likely that the 
transmission could have occurred in the gastrointesti-
nal tract. Bronchoalveolar lavage and sputum cultures 
during the patient’s first hospitalisation did not reveal 
the presence of C.  koseri or K.  pneumoniae or other 
bacteria. It could be hypothesised that, during his first 
hospitalisation, he was colonised in his gastrointesti-
nal tract by a K. pneumoniae of ST147, which predomi-
nates in this setting (unpublished data). A probable 
scenario is that the blaKPC-2 gene was transmitted from 
K.  pneumoniae to C.  koseri, since both are part of the 
gastrointestinal flora. Identification of a KPC-encoding 
C. koseri strain from faecal samples would provide sup-
port for this hypothesis. No such strain was isolated, 
but given the low minimum inhibitory concentration of 
imipenem against the C.  koseri isolate, a likely expla-
nation is that the imipenem concentration used for 
screening of faecal samples (1 mg/L) suppressed the 
growth of C. koseri.
Rapid spread of carbapenemase-producing 
Enterobacteriaceae is a serious concern in clinical 
patient care in Greece. The finding of an additional 
enterobacterial species, C.  koseri, producing KPC 
underscores the increasing clinical importance of car-
bapenemase-positive microorganisms in this country.
*Authors’ correction:
At the request of the authors, the word ‘anaerobic’ was de-
leted from the sentence ‘C. koseri, an environmental, anaer-
obic, Gram-negative bacterium, is occasionally found as a 
coloniser of the human gastrointestinal tract’. This change 
was made on 24 October 2011.
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